Disease Burden and Direct Health-Care Spending on Brain Conditions in Switzerland: Findings from the Global Burden of Disease 2023 Study for the Implementation of the Swiss Brain Health Plan

BackgroundBrain disorders are leading contributors to increasing disability and spending worldwide. In 2022 the Swiss Brain Health Plan (SBHP) was launched to promote brain health and prevent brain disorders. To guide the implementation of the SBHP, we performed a detailed analysis of the health and economic burden of brain disorders in Switzerland. MethodsWe analyzed Global Burden of Disease 2023 disability-adjusted life years (DALYs) and Institute for Health Metrics and Evaluation (IHME) cause-specific health-care spending estimates for Switzerland. DALYs were quantified for 1990 - 2023. Spending was analyzed for 2000 - 2019 across six types of care. We examined age and sex patterns, spending distribution, and international comparisons with six other countries (Germany, France, Denmark, Norway, Italy, Singapore). To assess short- and longer-term association between burden and spending estimates, we fitted panel regression models with disorder and year fixed effects under one-year and five-year lag specifications. FindingsBoth disease burden and spending were highly concentrated in a small number of conditions in Switzerland. In 2023, ten brain disorders accounted for 82{middle dot}9% of Switzerlands total DALY burden. In 2019, ten brain disorders accounted for 86{middle dot}0% of all direct brain-health spending, with dementia alone comprising 29{middle dot}5% of total expenditures. Among seven analyzed comparator countries, Switzerland had the highest per-capita brain-health spending and the highest spending per DALY. In fixed-effects panel models that accounted for spending persistence, lagged DALYs were not statistically associated with subsequent spending. Suicide prevention and addiction showed significant lower-than-expected health-sector spending (self-harm: {beta} = -0{middle dot}23; drug use disorders: {beta} = -0{middle dot}08 to -0{middle dot}18 across lag models). InterpretationBrain disorders generate a large burden in Switzerland. Within the IHME estimates, the burden-spending relationship over time appears limited. The implementation of the SBHP will refer to the current data and call for a burden-informed financing to guide strategic cross-sectorial allocation and prevention investments. Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe drew on evidence from the Global Burden of Disease (GBD) 2023 estimates on neurological and mental health conditions, and on cause-specific health-care spending data from the Institute for Health Metrics and Evaluation for Switzerland and selected high-income countries. These sources show that brain disorders are major contributors to disability and premature mortality, and that Switzerland is among the worlds highest spenders per capita on health care. Prior work has described the costs of individual brain disorders and drivers of health expenditure growth; however, it has often treated burden and spending as partly separate domains, leaving the country-level link between cause-specific disability-adjusted life-years (DALYs) and cause-specific spending, over time and in either direction, poorly characterized. Added value of this studyTo our knowledge, this is the first study in a single country to systematically link cause-specific DALYs and cause-specific direct health-care spending for brain disorders and to examine their longitudinal and bi-directional associations. Using harmonized GBD 2023 estimates and IHME 2019 cause-specific health spending data, we quantify the health and economic burden of 23 brain disorders in Switzerland across age, sex, care setting, and time, and benchmark patterns against six other high-income countries. By applying panel regression models with disorder and year fixed effects, we assess whether modeled spending shows any association with prior modeled burden once spending persistence is accounted for, and identify conditions with higher or lower spending relative to burden. Implications of all the available evidenceSwitzerland bears a major burden of brain disorders and devotes substantial resources to their care, yet within the modeled estimates, spending does not consistently correspond to burden over time. Disorders with long-standing multisectoral programs tended to show lower spending-to-burden ratios, suggesting that coordinated action beyond the health sector may reduce downstream health-sector demand. For Switzerland and similar health systems, these findings support national brain-health strategies that strengthen life-course prevention and early intervention, and that integrate financing with burden data to inform priority setting and periodic reassessment of resource allocation.